Please amend the application as follows:

In the Claims

1. (Amended) A method for altering angiogenesis in a mammal, comprising administering to the mammal, in a therapeutically effective quantity, a drug which alters [binding or] interaction of an artery-specific cell surface molecule with a vein-specific cell surface molecule in a therapeutically effective quantity.

5. (Amended) A method of Claim 3 wherein angiogenesis is enhanced and the drug enhances [binding or] interaction of the artery-specific Ephrin family ligand with its vein-specific Eph family receptor.

Please add the following claims:

--67. A method for altering angiogenesis in a mammal, comprising administering to the mammal, in a therapeutically effective quantity, a drug which alters binding of an artery-specific Ephrin family cell surface molecule with a vein-specific Eph family receptor, thereby altering angiogenesis.

68. A method for altering angiogenesis in a mammal, comprising administering to the mammal, in a therapeutically effective quantity, a drug which alters binding of EphrinB2 with EphB4, thereby altering angiogenesis.

69. A method for selectively delivering a drug to arteries in a mammal, comprising administering to the mammal a complex comprising:

a) the drug, and

b) a component which binds an artery-specific Ephrin family cell surface molecule, under conditions appropriate for the component of b) to bind said Ephrin family cell surface molecule, whereby the drug is delivered to the arteries.

70. The method of Claim 69, wherein the drug is an angiogenic drug.

71. A method for selectively delivering a drug to arteries in a mammal, comprising administering to the mammal a complex comprising:

a) the drug, and

b) a component which binds EphrinB2, under conditions appropriate for the component of b) to bind EphrinB2, whereby the drug is delivered to arteries.

72. The method of Claim 71, wherein the drug is an angiogenic drug.

73. A method for altering development of blood vessels in a mammal, comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of an artery-specific Ephrin family ligand or a soluble polypeptide comprising the extracellular domain of a vein-specific Eph family cell surface protein, thereby altering development of blood vessels.

74. A method for altering development of blood vessels in a mammal, comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of EphrinB2 or a soluble polypeptide comprising the extracellular domain of EphB4.

75. The method of Claim 8, where in the drug is angiogenic.--

REMARKS

Claims 1 and 5 have been amended to separate the terms 'interaction' and 'binding' into to separate sets of claims to avoid confusion. New Claims 67-75 have been added. No new matter has been added by these amendments.